FERLAY J , COLOMBET M , SOERJOMATARAM I , et al . Cancer statistics for the year 2020: an overview [J ] . Int J Cancer , 2021 . [Online ahead of print ]

HOWLADER N , ALTEKRUSE S F , LI C I , et al . US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status [J ] . J Natl Cancer Inst , 2014 , 106(5): dju055.

RIZZOLI R , BISCHOFF-FERRARI H , DAWSON-HUGHES B , et al . Nutrition and bone health in women after the menopause [J ] . Womens Health (Lond) , 2014 , 10 ( 6 ): 599 - 608 .

DIANA A N , CARLINO F , GIUNTA E F , et al . Cancer treatment-induced bone loss (CTIBL): state of the art and proper management in breast cancer patients on endocrine therapy [J ] . Curr Treat Options Oncol , 2021 , 22 ( 5 ): 45 . DOI: 10.1007/s11864-021-00835-2 http://doi.org/10.1007/s11864-021-00835-2 https://doi.org/10.1007/s11864-021-00835-2 https://doi.org/10.1007/s11864-021-00835-2

RACHNER T D , COLEMAN R , HADJI P , et al . Bone health during endocrine therapy for cancer [J ] . Lancet Diabetes Endocrinol , 2018 , 6 ( 11 ): 901 - 910 . DOI: 10.1016/S2213-8587(18)30047-0 http://doi.org/10.1016/S2213-8587(18)30047-0 https://linkinghub.elsevier.com/retrieve/pii/S2213858718300470 https://linkinghub.elsevier.com/retrieve/pii/S2213858718300470

LEE Y K , LEE E G , KIM H Y , et al . Osteoporotic fractures of the spine, hip, and other locations after adjuvant endocrine therapy with aromatase inhibitors in breast cancer patients: a meta-analysis [J ] . J Korean Med Sci , 2020 , 35 ( 46 ): e403 . DOI: 10.3346/jkms.2020.35.e403 http://doi.org/10.3346/jkms.2020.35.e403 https://jkms.org/DOIx.php?id=10.3346/jkms.2020.35.e403 https://jkms.org/DOIx.php?id=10.3346/jkms.2020.35.e403

BODY J J . Increased fracture rate in women with breast cancer: a review of the hidden risk [J ] . BMC Cancer , 2011 , 11 : 384 . DOI: 10.1186/1471-2407-11-384 http://doi.org/10.1186/1471-2407-11-384 http://bmccancer.biomedcentral.com/articles/10.1186/1471-2407-11-384 http://bmccancer.biomedcentral.com/articles/10.1186/1471-2407-11-384

CLYNES M A , HARVEY N C , CURTIS E M , et al . The epidemiology of osteoporosis [J ] . Br Med Bull , 2020 , 133 ( 1 ): 105 - 117 .

RASHKI KEMMAK A , REZAPOUR A , JAHANGIRI R , et al . Economic burden of osteoporosis in the world: a systematic review [J ] . Med J Islam Repub Iran , 2020 , 34 : 154 .

KEY T , APPLEBY P , BARNES I , et al . Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies [J ] . J Natl Cancer Inst , 2002 , 94 ( 8 ): 606 - 616 . DOI: 10.1093/jnci/94.8.606 http://doi.org/10.1093/jnci/94.8.606 https://academic.oup.com/jnci/article-lookup/doi/10.1093/jnci/94.8.606 https://academic.oup.com/jnci/article-lookup/doi/10.1093/jnci/94.8.606

FRANCIS P A , PAGANI O , FLEMING G F , et al . Tailoring adjuvant endocrine therapy for premenopausal breast cancer [J ] . N Engl J Med , 2018 , 379 ( 2 ): 122 - 137 . DOI: 10.1056/NEJMoa1803164 http://doi.org/10.1056/NEJMoa1803164 http://www.nejm.org/doi/10.1056/NEJMoa1803164 http://www.nejm.org/doi/10.1056/NEJMoa1803164

CUZICK J , SESTAK I , BAUM M , et al . Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial [J ] . Lancet Oncol , 2010 , 11 ( 12 ): 1135 - 1141 . DOI: 10.1016/S1470-2045(10)70257-6 http://doi.org/10.1016/S1470-2045(10)70257-6 https://linkinghub.elsevier.com/retrieve/pii/S1470204510702576 https://linkinghub.elsevier.com/retrieve/pii/S1470204510702576

REGAN M M , NEVEN P , GIOBBIE-HURDER A , et al . Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8.1 years median follow-up [J ] . Lancet Oncol , 2011 , 12 ( 12 ): 1101 - 1108 . DOI: 10.1016/S1470-2045(11)70270-4 http://doi.org/10.1016/S1470-2045(11)70270-4 https://linkinghub.elsevier.com/retrieve/pii/S1470204511702704 https://linkinghub.elsevier.com/retrieve/pii/S1470204511702704

NICKS K M , FOWLER T W , AKEL N S , et al . Bone turnover across the menopause transition: the role of gonadal inhibins [J ] . Ann N Y Acad Sci , 2010 , 1192 : 153 - 160 . DOI: 10.1111/j.1749-6632.2009.05349.x http://doi.org/10.1111/j.1749-6632.2009.05349.x https://onlinelibrary.wiley.com/doi/10.1111/j.1749-6632.2009.05349.x https://onlinelibrary.wiley.com/doi/10.1111/j.1749-6632.2009.05349.x

FOGELMAN I , BLAKE G M , BLAMEY R , et al . Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) [J ] . Osteoporos Int , 2003 , 14 ( 12 ): 1001 - 1006 . DOI: 10.1007/s00198-003-1508-y http://doi.org/10.1007/s00198-003-1508-y http://link.springer.com/10.1007/s00198-003-1508-y http://link.springer.com/10.1007/s00198-003-1508-y

HADJI P , ZILLER M , KIEBACK D G , et al . Effects of exemestane and tamoxifen on bone health within the tamoxifen exemestane adjuvant multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised substudy [J ] . Ann Oncol , 2009 , 20 ( 7 ): 1203 - 1209 . DOI: 10.1093/annonc/mdn762 http://doi.org/10.1093/annonc/mdn762 https://linkinghub.elsevier.com/retrieve/pii/S0923753419409964 https://linkinghub.elsevier.com/retrieve/pii/S0923753419409964

HADJI P , GNANT M , BODY J J , et al . Cancer treatment-induced bone loss in premenopausal women: a need for therapeutic intervention? [J ] . Cancer Treat Rev , 2012 , 38 ( 6 ): 798 - 806 . DOI: 10.1016/j.ctrv.2012.02.008 http://doi.org/10.1016/j.ctrv.2012.02.008 https://linkinghub.elsevier.com/retrieve/pii/S0305737212000291 https://linkinghub.elsevier.com/retrieve/pii/S0305737212000291

NUZZO F , GALLO C , LASTORIA S , et al . Bone effect of adjuvant tamoxifen, letrozole or letrozole plus zoledronic acid in early-stage breast cancer: the randomized phase 3 HOBOE study [J ] . Ann Oncol , 2012 , 23 ( 8 ): 2027 - 2033 . DOI: 10.1093/annonc/mdr600 http://doi.org/10.1093/annonc/mdr600 https://linkinghub.elsevier.com/retrieve/pii/S0923753419381086 https://linkinghub.elsevier.com/retrieve/pii/S0923753419381086

BURSTEIN H J , LACCHETTI C , ANDERSON H , et al . Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: ASCO clinical practice guideline focused update [J ] . J Clin Oncol , 2019 , 37 ( 5 ): 423 - 438 .

马远征 , 王以朋 , 刘强 , 等 . 中国老年骨质疏松诊疗指南(2018) [J ] . 中国老年学杂志 , 2019 , 39 ( 11 ): 2557 - 2575 .

MA Y Z , WANG Y P , LIU Q , et al . 2018 China guideline for the diagnosis and treatment of senile osteoporosis [J ] . Chin J Gerontol , 2019 , 39 ( 11 ): 2557 - 2575 .

COLEMAN R , HADJI P , BODY J J , et al . Bone health in cancer: ESMO clinical practice guidelines [J ] . Ann Oncol , 2020 , 31 ( 12 ): 1650 - 1663 . DOI: 10.1016/j.annonc.2020.07.019 http://doi.org/10.1016/j.annonc.2020.07.019 https://linkinghub.elsevier.com/retrieve/pii/S0923753420399956 https://linkinghub.elsevier.com/retrieve/pii/S0923753420399956

中国抗癌协会乳腺癌专业委员会 . 中国抗癌协会乳腺癌诊治指南与规范(2021年版) [J ] . 中国癌症杂志 , 2021 , 31 ( 10 ): 954 - 1040 .

The Society of Breast Cancer China Anti-Cancer Association . Guidelines for breast cancer diagnosis and treatment by China Anti-Cancer Association (2021 edition) [J ] . China Oncol , 2021 , 31 ( 10 ): 954 - 1040 .

HANDFORTH C , D'ORONZO S , COLEMAN R , et al . Cancer treatment and bone health [J ] . Calcif Tissue Int , 2018 , 102 ( 2 ): 251 - 264 . DOI: 10.1007/s00223-017-0369-x http://doi.org/10.1007/s00223-017-0369-x https://doi.org/10.1007/s00223-017-0369-x https://doi.org/10.1007/s00223-017-0369-x

WEAVER C M , ALEXANDER D D , BOUSHEY C J , et al . Calcium plus vitamin D supplementation and risk of fractures: an updated meta-analysis from the National Osteoporosis Foundation [J ] . Osteoporos Int , 2016 , 27 ( 1 ): 367 - 376 . DOI: 10.1007/s00198-015-3386-5 http://doi.org/10.1007/s00198-015-3386-5 https://link.springer.com/10.1007/s00198-015-3386-5 https://link.springer.com/10.1007/s00198-015-3386-5

HADJI P , AAPRO M S , BODY J J , et al . Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment [J ] . Ann Oncol , 2011 , 22 ( 12 ): 2546 - 2555 . DOI: 10.1093/annonc/mdr017 http://doi.org/10.1093/annonc/mdr017 https://linkinghub.elsevier.com/retrieve/pii/S0923753419343480 https://linkinghub.elsevier.com/retrieve/pii/S0923753419343480

中华医学会骨质疏松和骨矿盐疾病分会 . 原发性骨质疏松症诊疗指南(2017) [J ] . 中国全科医学 , 2017 , 20 ( 32 ): 3963 - 3982 . DOI: 10.3969/j.issn.1007-9572.2017.00.118 http://doi.org/10.3969/j.issn.1007-9572.2017.00.118

Chinese Society of Osteoporosis and Bone Mineral Research . Guidelines for the diagnosis and treatment of primary osteoporosis (2017) [J ] . Chin Gen Pract , 2017 , 20 ( 32 ): 3963 - 3982 .

邵志敏 , 沈镇宙 , 徐兵河 . 乳腺肿瘤学 [M ] . 上海 : 复旦大学出版社 , 2013 .

SHAO Z M , SHEN Z Z , XU B H . Breast oncology [M ] . Shanghai : Fudan University Press , 2013 .

MEI M , XIANG Z , YANG J , et al . Efficacy of zoledronic acid for prevention of bone loss in early-stage breast cancer patients receiving adjuvant therapy: a meta-analysis of 13 randomized controlled trials [J ] . Curr Probl Cancer , 2020 , 44 ( 2 ): 100507 .

中国医师协会肿瘤医师分会乳腺癌学组 , 中国抗癌协会国际医疗交流分会 . 骨改良药物安全性管理专家共识 [J ] . 中华肿瘤杂志 , 2021 , 43 ( 6 ): 622 - 628 .

Breast Cancer Division , Oncologist Branch of Chinese Medical Association; International Medical Exchange Branch of Chinese Anti-Cancer Association. Expert consensus on safety management of bone-modifying agents [J ] . Chin J Oncol , 2021 , 43 ( 6 ): 622 - 628 .

VEHMANEN L K , ELOMAA I , BLOMQVIST C P , et al . The effect of ovarian dysfunction on bone mineral density in breast cancer patients 10 years after adjuvant chemotherapy [J ] . Acta Oncol , 2014 , 53 ( 1 ): 75 - 79 . DOI: 10.3109/0284186X.2013.792992 http://doi.org/10.3109/0284186X.2013.792992 http://www.tandfonline.com/doi/full/10.3109/0284186X.2013.792992 http://www.tandfonline.com/doi/full/10.3109/0284186X.2013.792992

GNANT M F X , MLINERITSCH B , LUSCHIN-EBENGREUTH G , et al . Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group [J ] . J Clin Oncol , 2007 , 25 ( 7 ): 820 - 828 . DOI: 10.1200/JCO.2005.02.7102 http://doi.org/10.1200/JCO.2005.02.7102 http://ascopubs.org/doi/10.1200/JCO.2005.02.7102 http://ascopubs.org/doi/10.1200/JCO.2005.02.7102

GNANT M , MLINERITSCH B , LUSCHIN-EBENGREUTH G , et al . Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy [J ] . Lancet Oncol , 2008 , 9 ( 9 ): 840 - 849 . DOI: 10.1016/S1470-2045(08)70204-3 http://doi.org/10.1016/S1470-2045(08)70204-3 https://linkinghub.elsevier.com/retrieve/pii/S1470204508702043 https://linkinghub.elsevier.com/retrieve/pii/S1470204508702043

LESTER J E , DODWELL D , PUROHIT O P , et al . Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer [J ] . Clin Cancer Res , 2008 , 14 ( 19 ): 6336 - 6342 . DOI: 10.1158/1078-0432.CCR-07-5101 http://doi.org/10.1158/1078-0432.CCR-07-5101 http://clincancerres.aacrjournals.org/lookup/doi/10.1158/1078-0432.CCR-07-5101 http://clincancerres.aacrjournals.org/lookup/doi/10.1158/1078-0432.CCR-07-5101

LESTER J E , DODWELL D , BROWN J E , et al . Prevention of anastrozole induced bone loss with monthly oral ibandronate: final 5 year results from the ARIBON trial [J ] . J Bone Oncol , 2012 , 1 ( 2 ): 57 - 62 . DOI: 10.1016/j.jbo.2012.06.002 http://doi.org/10.1016/j.jbo.2012.06.002 https://linkinghub.elsevier.com/retrieve/pii/S2212137412000206 https://linkinghub.elsevier.com/retrieve/pii/S2212137412000206

GNANT M , PFEILER G , DUBSKY P C , et al . Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial [J ] . Lancet , 2015 , 386 ( 9992 ): 433 - 443 . DOI: 10.1016/S0140-6736(15)60995-3 http://doi.org/10.1016/S0140-6736(15)60995-3 https://linkinghub.elsevier.com/retrieve/pii/S0140673615609953 https://linkinghub.elsevier.com/retrieve/pii/S0140673615609953

ELLIS G K , BONE H G , CHLEBOWSKI R , et al . Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer [J ] . J Clin Oncol , 2008 , 26 ( 30 ): 4875 - 4882 . DOI: 10.1200/JCO.2008.16.3832 http://doi.org/10.1200/JCO.2008.16.3832 http://ascopubs.org/doi/10.1200/JCO.2008.16.3832 http://ascopubs.org/doi/10.1200/JCO.2008.16.3832

SHAPIRO C L , VAN POZNAK C , LACCHETTI C , et al . Management of osteoporosis in survivors of adult cancers with nonmetastatic disease: ASCO clinical practice guideline [J ] . J Clin Oncol , 2019 , 37 ( 31 ): 2916 - 2946 . DOI: 10.1200/JCO.19.01696 http://doi.org/10.1200/JCO.19.01696 https://ascopubs.org/doi/10.1200/JCO.19.01696 https://ascopubs.org/doi/10.1200/JCO.19.01696

NCCN clinical practice guidelines in oncology (breast cancer) (version 5.2021) [EB/OL ] . [ 2021 - 06 - 28 ] . http://www.nccn.org/patients http://www.nccn.org/patients http://www.nccn.org/patients.

BUNDRED N J , CAMPBELL I D , DAVIDSON N , et al . Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST study results [J ] . Cancer , 2008 , 112 ( 5 ): 1001 - 1010 . DOI: 10.1002/(ISSN)1097-0142 http://doi.org/10.1002/(ISSN)1097-0142 http://doi.wiley.com/10.1002/%28ISSN%291097-0142 http://doi.wiley.com/10.1002/%28ISSN%291097-0142

EIDTMANN H , DE BOER R , BUNDRED N , et al . Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST study [J ] . Ann Oncol , 2010 , 21 ( 11 ): 2188 - 2194 . DOI: 10.1093/annonc/mdq217 http://doi.org/10.1093/annonc/mdq217 https://linkinghub.elsevier.com/retrieve/pii/S0923753419395341 https://linkinghub.elsevier.com/retrieve/pii/S0923753419395341

COLEMAN R , DE BOER R , EIDTMANN H , et al . Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results [J ] . Ann Oncol , 2013 , 24 ( 2 ): 398 - 405 . DOI: 10.1093/annonc/mds277 http://doi.org/10.1093/annonc/mds277 https://linkinghub.elsevier.com/retrieve/pii/S0923753419368425 https://linkinghub.elsevier.com/retrieve/pii/S0923753419368425

DERENNE S , AMIOT M , BARILLÉ S , et al . Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment [J ] . J Bone Miner Res , 1999 , 14 ( 12 ): 2048 - 2056 . DOI: 10.1359/jbmr.1999.14.12.2048 http://doi.org/10.1359/jbmr.1999.14.12.2048 http://doi.wiley.com/10.1359/jbmr.1999.14.12.2048 http://doi.wiley.com/10.1359/jbmr.1999.14.12.2048

APARICIO A , GARDNER A , TU Y , et al . In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates [J ] . Leukemia , 1998 , 12 ( 2 ): 220 - 229 . DOI: 10.1038/sj.leu.2400892 http://doi.org/10.1038/sj.leu.2400892 https://doi.org/10.1038/sj.leu.2400892 https://doi.org/10.1038/sj.leu.2400892

FROMIGUE O , LAGNEAUX L , BODY J J . Bisphosphonates induce breast cancer cell death in vitro [J ] . J Bone Miner Res , 2000 , 15 ( 11 ): 2211 - 2221 . DOI: 10.1359/jbmr.2000.15.11.2211 http://doi.org/10.1359/jbmr.2000.15.11.2211 http://doi.wiley.com/10.1359/jbmr.2000.15.11.2211 http://doi.wiley.com/10.1359/jbmr.2000.15.11.2211

SENARATNE S G , PIRIANOV G , MANSI J L , et al . Bisphosphonates induce apoptosis in human breast cancer cell lines [J ] . Br J Cancer , 2000 , 82 ( 8 ): 1459 - 1468 . DOI: 10.1054/bjoc.1999.1131 http://doi.org/10.1054/bjoc.1999.1131 http://www.nature.com/doifinder/10.1054/bjoc.1999.1131 http://www.nature.com/doifinder/10.1054/bjoc.1999.1131

BOISSIER S , FERRERAS M , PEYRUCHAUD O , et al . Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases [J ] . Cancer Res , 2000 , 60 ( 11 ): 2949 - 2954 .

WOOD J , BONJEAN K , RUETZ S , et al . Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid [J ] . J Pharmacol Exp Ther , 2002 , 302 ( 3 ): 1055 - 1061 . DOI: 10.1124/jpet.102.035295 http://doi.org/10.1124/jpet.102.035295 http://jpet.aspetjournals.org/lookup/doi/10.1124/jpet.102.035295 http://jpet.aspetjournals.org/lookup/doi/10.1124/jpet.102.035295

COLEMAN R , WOODWARD E , BROWN J , et al . Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase Ⅲ trial (AZURE: BIG 01-04) for women with stage Ⅱ/Ⅲ breast cancer [J ] . Breast Cancer Res Treat , 2011 , 127 ( 2 ): 429 - 438 . DOI: 10.1007/s10549-011-1429-y http://doi.org/10.1007/s10549-011-1429-y http://link.springer.com/10.1007/s10549-011-1429-y http://link.springer.com/10.1007/s10549-011-1429-y

COLEMAN R , CAMERON D , DODWELL D , et al . Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial [J ] . Lancet Oncol , 2014 , 15 ( 9 ): 997 - 1006 . DOI: 10.1016/S1470-2045(14)70302-X http://doi.org/10.1016/S1470-2045(14)70302-X https://linkinghub.elsevier.com/retrieve/pii/S147020451470302X https://linkinghub.elsevier.com/retrieve/pii/S147020451470302X

COLEMAN R , HALL A , ALBANELL J , et al . Effect of MAF amplification on treatment outcomes with adjuvant zoledronic acid in early breast cancer: a secondary analysis of the international, open-label, randomised, controlled, phase 3 AZURE (BIG 01/04) trial [J ] . Lancet Oncol , 2017 , 18 ( 11 ): 1543 - 1552 . DOI: 10.1016/S1470-2045(17)30603-4 http://doi.org/10.1016/S1470-2045(17)30603-4 https://linkinghub.elsevier.com/retrieve/pii/S1470204517306034 https://linkinghub.elsevier.com/retrieve/pii/S1470204517306034

COLEMAN R E , COLLINSON M , GREGORY W , et al . Benefits and risks of adjuvant treatment with zoledronic acid in stage Ⅱ/Ⅲ breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01/04) [J ] . J Bone Oncol , 2018 , 13 : 123 - 135 . DOI: 10.1016/j.jbo.2018.09.008 http://doi.org/10.1016/j.jbo.2018.09.008 https://linkinghub.elsevier.com/retrieve/pii/S2212137418302628 https://linkinghub.elsevier.com/retrieve/pii/S2212137418302628

GNANT M , MLINERITSCH B , STOEGER H , et al . Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group trial 12 [J ] . Ann Oncol , 2015 , 26 ( 2 ): 313 - 320 . DOI: 10.1093/annonc/mdu544 http://doi.org/10.1093/annonc/mdu544 https://linkinghub.elsevier.com/retrieve/pii/S0923753419313912 https://linkinghub.elsevier.com/retrieve/pii/S0923753419313912

PERRONE F , DE LAURENTIIS M , DE PLACIDO S , et al . Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer: HOBOE phase 3 randomised trial [J ] . Eur J Cancer , 2019 , 118 : 178 - 186 . DOI: 10.1016/j.ejca.2019.05.004 http://doi.org/10.1016/j.ejca.2019.05.004 https://linkinghub.elsevier.com/retrieve/pii/S0959804919302977 https://linkinghub.elsevier.com/retrieve/pii/S0959804919302977

FRIEDL T W P , FEHM T , MÜLLER V , et al . Prognosis of patients with early breast cancer receiving 5 years vs 2 years of adjuvant bisphosphonate treatment: a phase 3 randomized clinical trial [J ] . JAMA Oncol , 2021 , 7 ( 8 ): 1149 - 1157 . DOI: 10.1001/jamaoncol.2021.1854 http://doi.org/10.1001/jamaoncol.2021.1854 https://jamanetwork.com/journals/jamaoncology/fullarticle/2781088 https://jamanetwork.com/journals/jamaoncology/fullarticle/2781088

Early Breast Cancer Trialists' Collaborative Group (EBCTCG) . Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials [J ] . Lancet , 2015 , 386 ( 10001 ): 1353 - 1361 . DOI: 10.1016/S0140-6736(15)60908-4 http://doi.org/10.1016/S0140-6736(15)60908-4 https://linkinghub.elsevier.com/retrieve/pii/S0140673615609084 https://linkinghub.elsevier.com/retrieve/pii/S0140673615609084

HE M F , FAN W D , ZHANG X Q . Adjuvant zoledronic acid therapy for patients with early stage breast cancer: an updated systematic review and meta-analysis [J ] . J Hematol Oncol , 2013 , 6 ( 1 ): 80 . DOI: 10.1186/1756-8722-6-80 http://doi.org/10.1186/1756-8722-6-80 https://doi.org/10.1186/1756-8722-6-80 https://doi.org/10.1186/1756-8722-6-80

HUANG W W , HUANG C , LIU J , et al . Zoledronic acid as an adjuvant therapy in patients with breast cancer: a systematic review and meta-analysis [J ] . PLoS One , 2012 , 7 ( 7 ): e40783 . DOI: 10.1371/journal.pone.0040783 http://doi.org/10.1371/journal.pone.0040783 https://dx.plos.org/10.1371/journal.pone.0040783 https://dx.plos.org/10.1371/journal.pone.0040783

GNANT M , PFEILER G , STEGER G G , et al . Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial [J ] . Lancet Oncol , 2019 , 20 ( 3 ): 339 - 351 . DOI: 10.1016/S1470-2045(18)30862-3 http://doi.org/10.1016/S1470-2045(18)30862-3 https://linkinghub.elsevier.com/retrieve/pii/S1470204518308623 https://linkinghub.elsevier.com/retrieve/pii/S1470204518308623

COLEMAN R , FINKELSTEIN D M , BARRIOS C , et al . Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial [J ] . Lancet Oncol , 2020 , 21 ( 1 ): 60 - 72 . DOI: 10.1016/S1470-2045(19)30687-4 http://doi.org/10.1016/S1470-2045(19)30687-4 https://linkinghub.elsevier.com/retrieve/pii/S1470204519306874 https://linkinghub.elsevier.com/retrieve/pii/S1470204519306874

EISEN A , SOMERFIELD M R , ACCORDINO M K , et al . Use of adjuvant bisphosphonates and other bone-modifying agents in breast cancer: ASCO-OH (CCO) guideline update [J ] . J Clin Oncol , 2022 . [Online ahead of print ]

GREGORY W , MARSHALL H , BELL R , et al . Adjuvant zoledronic acid (ZOL) in postmenopausal women with breast cancer and those rendered postmenopausal: results of a meta-analysis [J ] . J Clin Oncol , 2012 , 30 ( 15_suppl ): 513 .